Slide 1: Investor Presentation Q4 and FY24
Alembic Pharmaceuticals Limited Investor Presentation Q4 and FY24 May 9, 2024
Slide 2: Safe Harbour Statement
Safe Harbour Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diff
Slide 3: Quarterly Snapshot
Quarterly Snapshot INR Bn Key Highlights : 8% YoY India Branded Business : India Branded Business Revenue R&D recorded 3% growth with topline of INR 5.03 billion 15.17 -7% QoQ 8% of Sales for Q4 FY24. US Generics : Growth of 19% on YoY basis led by 7 new launches in the quarter and market share gain
Slide 4: Revenue Snapshot
Revenue Snapshot INR Bn Business Q4 FY24 Q4 FY23 Y-o-Y Q3FY24 Q-o-Q FY24 FY23 Y-o-Y Formulations India 5.03 4.90 3% 5.96 -16% 22.00 20.63 7% US 4.23 3.54 19% 4.74 -11% 17.30 15.72 10% Ex-US 2.62 2.49 5% 2.72 -4% 10.52 8.52 23% API 3.30 3.13 5% 2.89 14% 12.46 11.66 7% Total Revenue 15.17 14.06 8% 16.
Slide 5: Diversified Therapy Presence
Diversified Therapy Presence Revenue – Q4 FY 24 Revenue - FY 24 INR Bn INR Bn CAGR : 11.4% 22.00 Growth: 3% 20.63 19.30 4.90 5.03 Vet 14.30 15.00 Acute 0.61 0.82 1.70 1.48 Specialty 2.58 2.73 Q4FY23 Q4FY24 FY20 FY21 FY22 FY23 FY24 Sales Mix – Q4 FY 24 Anti Infective India Branded Business recorded
Slide 6: Branded Business – Rx driven rankings
Branded Business – Rx driven rankings Top Brands with Rank and Market Share Driving overall Prescription Business *Figures in Mn Rank MS% Rank MS% BRANDS MAT MAT BRANDS MAT MAT 130.2 0.233 47 FY 24* FY 24 FY 24* FY 24 AZITHRAL 1 32.5 WIKORYL 3 10.4 MAT Mar 24 ALTHROCIN 1 88.3 SHARKOFERROL 3 6.2 MAT
Slide 7: High focus therapies outgrowing market
High focus therapies outgrowing market Gynecology, Gastrointestinal, Anti Diabetic and Ophthalmology outpaced market growth. Performed relatively better than the market in Antibiotic and Respiratory segments on high base in previous year. FY24 Growth Comparison Therapy APL Market* Net Growth Gyn
Slide 8: New Launches
New Launches New launches continue to do well along with promising future launches across key segments. FY24 Therapy Molecule Brands Launch INR Mn Dydrogesterone ISOFIT 2022 598 Gynecology Iron Ferric RICHAR-FCM 2023 42 ULGERAFT 2022 185 Gastrointestinal Raft Mkt EVARAFT 2024 74 VOAGE-S 2022 78 Dapa
Slide 9: Animal Health Business
Animal Health Business Revenue – Q4 FY24 Revenue – FY24 Growth 34% CAGR 25.1% 3,555 2,800 2,360 Q4FY23 820 1,864 Q4FY24 1,453 610 Q4FY23 Q4FY24 FY20 FY21 FY22 FY23 FY24 Sales Mix – Q4 FY24 Operating in Livestock and Poultry market Antibiotic 40% Established new division with 350 headcount. Lea
Slide 10: Technology transforming business
Technology transforming business Deployment of Ipads for MR interaction with the Healthcare Medical Professional’s (HMP’s) - Upgrading our scope to communicate medico-marketing content to the HMP for our brands along with an increased time spend during calls. Upgraded to SalesForce platform for
Slide 11: US Generics market stabilizing…
US Generics market stabilizing… Revenue- Q4 FY24 Revenue – Last 5 years INR Bn INR Bn Growth 19% 4.23 21.63 3.54 19.76 17.30 16.66 15.72 Q4FY23 Q4FY24 FY20 FY21 FY22 FY23 FY24 Approved ANDAs Injectable 12 Inhalation Derma 2 Well-established US front end with strong customer base 27 7 products laun
Slide 12: …ex-US market showing exceptional growth…
…ex-US market showing exceptional growth… Revenue – Q4 FY24 Revenue – Last 5 years INR Bn 2.62 INR Bn 2.49 Growth 5% CAGR: 21% 10.52 8.52 7.79 7.75 Q4FY23 Q4FY24 Strong momentum delivering growth of 23% on annual basis led by robust demand across the regions. 4.97 Ex-US driven by partnership in fo
Slide 13: …and API market rising steadily
…and API market rising steadily Revenue – Q4 FY24 Revenue – Last 5 years INR Bn INR Bn 3.30 3.13 Growth 5% CAGR: 15% 12.46 11.66 9.55 9.39 Q4FY23 Q4FY24 7.08 Growth of 7% on annual basis is led by surge in volumes, partially offset by price erosion across the markets. 1 US DMF filed in FY24. 132 C
Slide 14: R&D investments set to decline
R&D investments set to decline Dosage form wise ANDA approval and Launch R&D Capabilities Q4FY24 FY24 Dosage Forms Formulation : Vadodara and Hyderabad Approval* Launch Approval Launch OSD 1 3 9 10 API : Vadodara and Hyderabad Injectable - Gen 0 0 3 5 Bio Centre : Vadodara Injectable - Onco 0 1 1 4
Slide 15: Yearly Financials
Yearly Financials Revenue INR Bn EBIDTA Net Profit INR Bn INR Bn 16.31 11.78 62.29 10.53 # 9.61 56.53 7.79 # 6.65 # 6.16 53.93 4.97 # 53.06 FY21 FY22 FY23 FY24 FY21 FY22 FY23 FY24 FY21 FY22 FY23 FY24 EBIDTA margin % Capex INR Bn ROCE % 41 * 30 6.87 20 # 4.67 25*# 15 4.12 14 # 3.45 14*# 15 FY21 FY22
Slide 16: Enhancing ESG compliance
Sustainability Enhancing ESG compliance Commissioned 12 MW Solar park at Bhatpur, Gujarat Targets: Developed 82 Nos. of recharge well and planted 20,000 Trees so far 19% Reduction in Indirect Energy Consumption 28% Reduction in Water Consumption(KL/MT) Net-Zero by 2040 16% Reduction (YoY) in To
Slide 17: Strategic Roadmap
Strategic Roadmap Business Initiatives in FY24 Plan for FY25 • Increased focus on the animal health space with therapy leading products. • Improve depth in the current strength with new launches • Deployment of Ipads for MR interaction with the planned in FY 25 & launches done in FY 24. The India Bu
Slide 18: Company Overview
ehe eS —— Touching Lives “Dy Company Overview
Slide 19: Company at a Glance
Company at a Glance Mission Prescribers in India Improve healthcare with innovation, commitment and trust 2,33,000 Team size Field Force 14,500 + 5,000 + Brands Manufacturing facilities 9 191 ANDA filings Net Zero 260 (Mar 31, 2024) 2040 R&D Centres Products in US 2 147
Slide 20: Value Proposition
Value Proposition Developing Supplying APIs Ranks 20th in the specialty drug to 60+ countries Indian formulations pipeline for India globally market Exploring Consistent and Established a opportunities in High Dividend presence in Chile Injectables Payout & UAE Strengthening presence Expanding in Ca
Slide 21: The Journey
The Journey 1907 2007 2008 2009 2010 2012 2006 Acquired Dabur’s FDA approved Pharmaceutical Established by FDA approved Indian Cardiology, FDA approved API facility FDA approved Multiple divisions to business demerged Formed a JV, Amin Family GI and Gynecology Formulation address chronic API facilit
Slide 22: Robust Infrastructure
Robust Infrastructure Last USFDA Location Dosage Form Audit International Generics F1 – Panelav General Oral Solids Mar’20 Oncology Oral Solids Mar’24 F2 – Panelav Oncology Injectables Mar’24 F2 - F3 - General Injectables Panelav Karkhadi F3 – Karkhadi Ophthalmic Mar’23 F4 – Jarod General Oral Solid
Slide 23: Thank you
For further queries, please contact: Mr. Ajay Desai ajay.desai@alembic.co.in 022-6695 3999 Mr. Mitanshu Shah mitanshu.shah@alembic.co.in 0265-663 7630 Thank you Investor Relations Advisors : Adfactors PR Pvt. Ltd. Snighter Albuquerque snighter.a@adfactorspr.com Darshan Mankad darshan.mankad@adfactor